Eugene Oh

Mr. Eugene Oh

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CNCharles B. Nguyen
Charles B. Nguyen
EOEugene Oh
Eugene Oh
PBPiroz Bahar
Piroz Bahar
UVUlka N. Vaishampayan
Ulka N. Vaishampayan
TETobias Else
Tobias Else
AAAjjai S. Alva
Ajjai S. Alva
Germline inactivation of the Von Hippel-Lindau (VHL) tumor suppressor is the defining hallmark in hereditary VHL disease and VHL-associated renal cell carcinoma (RCC). However, somatic VHL mutations are also observed in patients with sporadic RCC. Loss of function VHL mutations result in constitutive activation of hypoxia-inducible factor-2 alpha (HIF-2α), which leads to increased expression of HIF target genes that promote angiogenesis and tumor growth. As of 2023, belzutifan is currently the only approved HIF-2α inhibitor for both VHL-associated and sporadic metastatic RCC (mRCC). However, there is potential for resistance with HIF-2α inhibitors which warrants novel HIF-2α-targeting strategies. In this review, we discuss the potential resistance mechanisms with belzutifan and current clinical trials evaluating novel combinations of belzutifan with other targeted therapies and immune checkpoint inhibitors which may enhance the efficacy of HIF-2α targeting. Lastly, we also discuss newer generation HIF-2α inhibitors that are currently under early investigation and outline future directions and challenges with HIF-2α inhibitors for mRCC.

1 October 2025 in Cancer Medicine
Verified
Journal Article
Open access
ANAmanda Nizam
Amanda Nizam
CNCharles B. Nguyen
Charles B. Nguyen
JLJinju Li
Jinju Li
EZEmily C. Zabor
Emily C. Zabor
Pavlos MsaouelPavlos Msaouel
Pavlos Msaouel
VKVadim S Koshkin
Vadim S Koshkin
Introduction: Enfortumab vedotin‐ejfv (EV), an antibody–drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real‐world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV‐related dermatologic toxicities, but survival implications remain unclear. This analysis assessed the safety of EV monotherapy and the impact of dermatologic and neurologic toxicities on efficacy outcomes in a multi‐institutional cohort. Materials and Methods: UNITE is a multicenter, retrospective study across 16 US sites of patients with aUC treated with targeted agents, including EV. Primary endpoints were the incidence of EV treatment‐related adverse events (TRAEs, any grade) and TRAE‐related treatment modifications. Secondary endpoints included a comparison of ORR, progression‐free survival (PFS), and overall survival (OS) between patients with and without dermatologic toxicities and neuropathy. To reduce immortal time bias, Cox regression models incorporated TRAEs as time‐dependent covariates to adjust for EV treatment duration as well as Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, and liver metastases. Results: Between 2018 and 2023, 485 patients with aUC received > 1 dose of EV monotherapy. Most (67%) received > 2 prior therapy lines. Any grade TRAEs occurred in 77%, most frequently neuropathy (36%) and dermatologic toxicities (27%); 57% required treatment modification and 21% discontinued EV, primarily due to neuropathy (9%) and fatigue (3%). Patients with dermatologic toxicities and neuropathy had higher ORR (56% vs. 42%; p = 0.007 and 64% vs. 35%; p < 0.0001, respectively). Neuropathy was independently associated with improved OS (HR 0.66; 95% CI 0.50–0.87; p = 0.002); dermatologic TRAEs were not associated with PFS or OS benefit. Conclusions: EV safety outside clinical trials was consistent with prior reports, with no new signals. Treatment modifications were most often due to neuropathy, dermatologic toxicities, and fatigue. Both dermatologic toxicities and neuropathy correlated with higher ORR, but only neuropathy was independently associated with improved OS.

9 October 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
EOEugene Oh
Eugene Oh
YCYe Chua
Ye Chua
PBPiroz Bahar
Piroz Bahar
MAMarie-Louise Accardo
Marie-Louise Accardo
XLXiaochen Li
Xiaochen Li
CNCharles B. Nguyen
Charles B. Nguyen

10 January 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AJAlbert Jang
Albert Jang
TJTanya Jindal
Tanya Jindal
AKAli Raza Khaki
Ali Raza Khaki
CJCindy Y. Jiang
Cindy Y. Jiang
OAOmar Alhalabi
Omar Alhalabi
JBJason R Brown
Jason R Brown